UB Paderborn / Katalog / Suche / in CDI

Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer

Clinical colorectal cancer, 2012-09, Vol.11 (3), p.155-166

Cartwright, Thomas H

2012

Volltextzugriff (PDF)

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

The lancet oncology, 2012-12, Vol.13 (12), p.1225-1233

2012

Volltextzugriff (PDF)

Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity

Cancer, 2017-01, Vol.123 (2), p.345-356

2017

Volltextzugriff (PDF)

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials

The lancet oncology, 2014-12, Vol.15 (13), p.1481-1492

2014

Volltextzugriff (PDF)

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

The New England journal of medicine, 2004-06, Vol.350 (23), p.2335-2342

2004

Volltextzugriff (PDF)

Adverse Events Associated With Antiangiogenic Agents in Combination With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer and Their Management

Clinical colorectal cancer, 2013-06, Vol.12 (2), p.86-94

Cartwright, Thomas H

2013

Volltextzugriff (PDF)

Effects of a Brief Multimedia Psychoeducational Intervention on the Attitudes and Interest of Patients With Cancer Regarding Clinical Trial Participation: A Multicenter Randomized Controlled Trial

Journal of clinical oncology, 2012-07, Vol.30 (20), p.2516-2521

2012

Volltextzugriff (PDF)

Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting

Drugs -- real world outcomes, 2018-09, Vol.5 (3), p.149-159

2018

Volltextzugriff (PDF)

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

Cancer, 2013-07, Vol.119 (14), p.2555-2563

2013

Volltextzugriff (PDF)

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

Journal of clinical oncology, 2007-01, Vol.25 (1), p.102-109

2007

Volltextzugriff (PDF)

Morgagni hernia presenting as constipation in the postsurgical patient: A case report

International journal of abdominal wall and hernia surgery, 2023-01, Vol.6 (1), p.44-47

2023

Volltextzugriff (PDF)

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study

Cancers, 2020-03, Vol.12 (3), p.657

2020

Volltextzugriff (PDF)

Repositioning Fenofibrate to Reactivate p53 and Reprogram the Tumor-Immune Microenvironment in HPV+ Head and Neck Squamous Cell Carcinoma

Cancers, 2022-01, Vol.14 (2), p.282

2022

Volltextzugriff (PDF)

Survival Outcomes of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Treated in US Community Oncology

Clinical colorectal cancer, 2012-12, Vol.11 (4), p.238-246

2012

Volltextzugriff (PDF)

Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2224-2226

2008

Volltextzugriff (PDF)

Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network

Cancer control, 2008-10, Vol.15 (4), p.308-313

2008

Volltextzugriff (PDF)

Florida Initiative for Quality Cancer Care: Improvements in Breast Cancer Quality Indicators During a 3-Year Interval

Journal of the American College of Surgeons, 2014-10, Vol.219 (4), p.638-645.e1

2014

Volltextzugriff (PDF)

Florida Initiative for Quality Cancer Care: Improvements on Colorectal Cancer Quality of Care Indicators during a 3-Year Interval

Journal of the American College of Surgeons, 2014-01, Vol.218 (1), p.16-25.e4

2014

Volltextzugriff (PDF)

Successful Administration of Panitumumab Alone After Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer

Clinical colorectal cancer, 2008-05, Vol.7 (3), p.202-203

2008

Volltextzugriff (PDF)

Pathways, outcomes, and costs in colon cancer: retrospective evaluations in 2 distinct databases

The American journal of managed care, 2011-05, Vol.17 Suppl 5 Developing, p.SP45-SP52

2011

Volltextzugriff (PDF)

Successful Administration of Panitumumab Alone After Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer

Clinical colorectal cancer, 2009, Vol.8, p.15-16

2009

Volltextzugriff (PDF)

Initial evaluation of quality indicators for psychosocial care of adults with cancer

Cancer control, 2009-10, Vol.16 (4), p.328-334

2009

Volltextzugriff (PDF)

A randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.TPS779-TPS779

2016

Volltextzugriff (PDF)

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey

Pharmaceuticals (Basel, Switzerland), 2017-01, Vol.10 (1), p.19

2017

Volltextzugriff (PDF)

Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.212-212

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Adverse Events Associated With Antiangiogenic Agents in Combination With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer and Their Management

Effects of a Brief Multimedia Psychoeducational Intervention on the Attitudes and Interest of Patients With Cancer Regarding Clinical Trial Participation: A Multicenter Randomized Controlled Trial

Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

Morgagni hernia presenting as constipation in the postsurgical patient: A case report

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study

Repositioning Fenofibrate to Reactivate p53 and Reprogram the Tumor-Immune Microenvironment in HPV+ Head and Neck Squamous Cell Carcinoma

Survival Outcomes of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Treated in US Community Oncology

Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer

Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network

Florida Initiative for Quality Cancer Care: Improvements in Breast Cancer Quality Indicators During a 3-Year Interval

Florida Initiative for Quality Cancer Care: Improvements on Colorectal Cancer Quality of Care Indicators during a 3-Year Interval

Successful Administration of Panitumumab Alone After Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer

Pathways, outcomes, and costs in colon cancer: retrospective evaluations in 2 distinct databases

Successful Administration of Panitumumab Alone After Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer

Initial evaluation of quality indicators for psychosocial care of adults with cancer

A randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey

Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE

Suchergebnisse filtern